Bristol-Myers Squibb: News
 
Partnering News
July 26, 2016Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung CancerJuly 25, 2016AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy RegimenJuly 5, 2016Bristol-Myers Squibb Acquires Cormorant PharmaceuticalsJune 30, 2016Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and EnadenotucirevApril 1, 2016Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.March 23, 2016Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.February 16, 2016Bristol-Myers Squibb and Dana-Farber Cancer Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research ProgramFebruary 1, 2016Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in JapanDecember 18, 2015Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV HealthcareDecember 14, 2015Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research ProgramDecember 8, 2015Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.December 8, 2015Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton UniversityDecember 4, 2015Bristol-Myers Squibb Receives Multiple Myeloma Research Foundation’s 2015 Collaborator AwardNovember 2, 2015Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.October 15, 2015Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody ProgramSeptember 25, 2015Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy ProgramAugust 31, 2015Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Development for Fibrotic DiseasesAugust 30, 2015Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology AntibodiesJuly 29, 2015Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.July 15, 2015MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic DiseasesApril 16, 2015Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North AmericaApril 8, 2015Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.April 6, 2015Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular DiseasesMarch 24, 2015Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 4, 2015Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.